Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 88 people with Fragile X Syndrome or Creatine Transporter Deficiency to test a new imaging technology that can see how the brain works. Both of these are genetic conditions that affect how the brain develops and cause intellectual disability. This study might help doctors better understand and diagnose these conditions in the future.
WHY IT MATTERSThis trial is recruiting patients with two of the most common X-linked intellectual disability disorders and may provide a new diagnostic tool that could improve how these conditions are identified and monitored.
Clinical trialCLINICALTRIALSApr 1
This is a continuation study for patients who are already taking the cancer drugs dabrafenib and/or trametinib and have done well on them. If your doctor thinks you're still benefiting from these medications after your original trial ends, you may be able to keep taking them through this new study. The study is looking for about 100 patients with various types of cancer including melanoma, lung cancer, and brain tumors.
WHY IT MATTERSThis rollover study allows patients whose cancers are responding well to dabrafenib and/or trametinib to continue access to these drugs after their original trial ends, rather than losing treatment.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 3,100 people to join a study about why patients don't take their medications as prescribed. The study will test a new approach to help people stick to their treatment plans, which could improve their health and reduce unnecessary hospital visits. About half of all patients don't take their medicines the right way, and this problem gets worse when treatment also requires lifestyle changes.
WHY IT MATTERSThis trial directly addresses medication non-adherence across multiple rare disease categories, meaning patients with rare conditions could benefit from proven strategies to better manage their treatments and health outcomes.
ResearchCONGRESSApr 1
Researchers studied how life circumstances like poverty, access to healthcare, and education affect children with developmental delays and intellectual disabilities. They also looked at how long it takes families to get a diagnosis and whether genetic testing helps. The study suggests that where you live and your resources matter a lot in getting answers for why a child has developmental challenges.
WHY IT MATTERSThis research highlights that children from disadvantaged backgrounds face longer diagnostic journeys for developmental delays—meaning families may wait years longer to understand their child's condition and access support services.
ResearchPUBMEDApr 1
Scientists are developing a new technology called Digital Twins—computer models that act like virtual copies of individual patients. These virtual copies could help doctors diagnose rare childhood diseases faster and find better treatments by testing ideas on the computer before trying them on real patients. This is especially helpful for rare diseases because there aren't many patients to study, and it's hard to do traditional research on children.
WHY IT MATTERSDigital twins could speed up diagnosis and enable personalized treatment plans for children with rare diseases, potentially reducing the years of diagnostic delay that currently affects most pediatric rare disease patients.
ResearchPUBMEDApr 1
Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.
WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
ResearchPUBMEDApr 1
Researchers in Turkey tested a new questionnaire called the Parental Needs Scale for Rare Diseases to measure what parents of children with rare diseases need most. The study included 264 parents and used statistical tests to make sure the questionnaire works well and gives consistent results. This tool can help doctors and support programs better understand and meet the needs of families dealing with rare diseases.
WHY IT MATTERSThis validated assessment tool enables healthcare systems to systematically identify and address the specific economic, emotional, and physical support needs of parents caring for children with rare diseases, potentially improving family quality of life and care outcomes.
ResearchPUBMEDApr 1
Researchers in Italy tested a new way to diagnose rare genetic diseases in children using whole genome sequencing—a test that reads all of a person's genetic code. Between 2018 and 2022, they studied 64 children with complex neurological problems that doctors couldn't figure out. This study shows whether this genetic test could help find answers faster for kids with mysterious rare diseases.
WHY IT MATTERSIf your child has unexplained neurological symptoms and multiple doctors haven't found a diagnosis, this research demonstrates that whole genome sequencing through healthcare systems may finally provide answers—potentially ending years of diagnostic uncertainty.
PolicyPUBMEDApr 1
A European network for rare connective tissue diseases has created a new model where patients are treated as equal partners in research and care decisions. Instead of doctors alone deciding what to study and how to treat patients, this network includes patients in every step—from identifying problems to writing research papers together. This approach helps address long diagnostic delays and gaps in care that patients with these rare diseases often face.
WHY IT MATTERSPatients with rare connective tissue diseases can now directly influence research priorities and treatment approaches through structured partnership roles, rather than having decisions made without their input.
ResearchPUBMEDApr 1
Scientists are developing a new way to study rare bone diseases using lab-grown bone tissue called organoids. Instead of only using animal tests or simple cell cultures, researchers can now grow tiny bone structures that act like real bones. This helps them understand why these diseases happen and test new treatments more accurately before trying them in patients.
WHY IT MATTERSFor patients with rare skeletal disorders, bone organoids could speed up the discovery of treatments by allowing researchers to test drugs on disease-specific bone tissue grown from patient cells, potentially leading to personalized medicine approaches.
ResearchPUBMEDApr 1
Doctors are getting better at using a special imaging machine called PET/MR that combines two types of scans to diagnose rare diseases in children. This machine is especially helpful because it takes clearer pictures while using less radiation than older machines, which is important for kids. The machine works well for finding tumors, genetic disorders, and inflammatory diseases, and doctors can use it to check how well treatments are working.
WHY IT MATTERSIf your child has a rare disease requiring imaging, PET/MR technology may reduce their radiation exposure and the number of separate scans needed compared to traditional imaging methods.
PolicyPUBMEDApr 1
Researchers compared how quickly rare disease drugs become available in China versus the United States between 2001 and 2024. The study looked at a problem called 'drug loss' — when medicines are approved in the US but never reach Chinese patients — and 'drug lag' — when there's a long delay before Chinese approval. The findings help the Chinese government understand what's blocking patients from getting treatments that already exist elsewhere in the world.
WHY IT MATTERSIf you have a rare disease in China, this research directly impacts whether you can access treatments that may already be approved and available in the United States, potentially identifying barriers your doctor or patient advocacy groups can help address.
ResearchPUBMEDApr 1
Researchers reviewed 78 studies about early satiety (feeling full quickly after eating small amounts) in cancer patients. They found this symptom is common but often overlooked, and doctors don't have consistent ways to measure or describe it. The review shows there are big gaps in how we understand and treat this problem for cancer patients.
WHY IT MATTERSEarly satiety causes cancer patients to eat less and lose weight, which can weaken their ability to fight cancer and recover from treatment—but doctors rarely screen for or address this specific symptom.
ResearchPUBMEDApr 1
Researchers in Brazil studied dental care for children and teens with rare diseases at five specialized centers. They found that over 1,000 young patients with 244 different rare diseases received dental treatment, with blood-related diseases being the most common. On average, kids didn't see a dentist for the first time until age 8, and many had to travel far from home to get specialized dental care.
WHY IT MATTERSThis study shows that children with rare diseases often wait years before receiving dental care and face significant travel barriers—highlighting a critical gap in specialized dental services that families should advocate for in their own communities.
ResearchPUBMEDApr 1
Researchers tested whether people could get genetic testing (genome sequencing) without always needing to see a genetics specialist first. They studied 313 people of all ages who had unexplained symptoms and could refer themselves or be referred by any doctor. The study found that people who referred themselves were just as likely to get a diagnosis as those referred by specialists. This suggests a new way to make genetic testing available to more people while still having genetics experts review the results.
WHY IT MATTERSIf this hybrid model works, patients with rare diseases could access genome sequencing faster and more easily without waiting for a genetics specialist appointment, potentially shortening the diagnostic odyssey that many rare disease patients experience.
Clinical trialCLINICALTRIALSMar 31
Researchers are building a large international database to collect information and tissue samples from children, teens, and young adults with rare brain tumors. By gathering this data from 5,800 patients, scientists hope to better understand these uncommon cancers and develop better treatments. The study is currently looking for patients to participate.
WHY IT MATTERSThis registry directly addresses rare brain tumors like astroblastoma and BCOR ITD sarcoma that have limited research data—participating patients contribute to the only large-scale international effort to understand these specific tumor types.
ResearchCLINICALTRIALSMar 30
This study is looking for 2,800 people to help researchers understand how being a caregiver affects a person's health and stress levels over time. The study includes caregivers of people with rare diseases like Batten disease, Tay-Sachs disease, and other inherited metabolic disorders, as well as caregivers of people with undiagnosed diseases. By learning more about caregiver stress, researchers hope to find ways to better support the millions of unpaid family caregivers in the U.S.
WHY IT MATTERSIf you or a family member care for someone with a rare inherited metabolic disorder, Batten disease, Tay-Sachs, or an undiagnosed disease, this study directly addresses the health challenges caregivers face and could lead to better support resources.
ResearchCLINICALTRIALSMar 30
Researchers at Children's National completed a study testing a new support program for parents of children with rare diseases. The program, called Rare Group Problem Management Plus, brought parents together once a week for 5 weeks to help them manage stress, anxiety, and emotional challenges. The small study included 8 parents and focused on teaching practical coping skills in a group setting where everyone had similar experiences.
WHY IT MATTERSThis completed trial demonstrates that group-based support programs specifically designed for parents of children with rare conditions can address the significant mental health burden these families face, potentially offering a scalable model for other rare disease communities.
ResearchBIORXIVMar 30
Researchers developed a new computer tool called PhenoSS that helps doctors diagnose rare diseases more accurately by analyzing patient symptoms in a smarter way. Instead of just matching symptoms one-by-one, this tool understands how symptoms relate to each other and accounts for differences in how different doctors record patient information. This could help patients get diagnosed faster and more correctly.
WHY IT MATTERSIf this tool becomes available in clinical practice, patients with rare diseases could receive accurate diagnoses faster by having their symptom patterns analyzed more intelligently, potentially reducing the average diagnostic odyssey timeline.
ResearchBIORXIVMar 30
Researchers are testing whether artificial intelligence programs called large language models can help doctors decide which genetic tests to order for patients with rare diseases. Instead of doctors having to memorize complicated guidelines, the AI could read the patient's information and recommend whether a simple gene panel or a more complete genetic test would be best. This could make the process faster and more consistent across different hospitals.
WHY IT MATTERSIf this AI tool works well, patients with rare diseases could get the right genetic test recommended faster, potentially leading to quicker diagnoses and treatment decisions.